Managing chikungunya arthritis using etanercept

Simple item page
dc.contributor.authorV, Haridasen_US
dc.contributor.authorK, Haridasen_US
dc.date.accessioned2020-10-16T08:09:05Z
dc.date.available2020-10-16T08:09:05Z
dc.date.issued2019-08
dc.description.abstractChikungunya virus or Aedes-borne alpha virus causes infection through an acute viremic phase and can be complicatedwith a chronic arthritis phase. The present case highlights the benefits of using etanercept for managing chikungunyaarthritis, especially in scenarios where NSAIDS and steroids are contraindicated due to multiple comorbidities.en_US
dc.identifier.affiliationsArthritis Super Speciality Center, Hubli, Karnataka, Indiaen_US
dc.identifier.citationV Haridas, K Haridas. Managing chikungunya arthritis using etanercept. Internet Journal of Rheumatology and Clinical Immunology. 2019 Aug; 7(1): 1-3en_US
dc.identifier.issn2320-7221
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/208143
dc.languageenen_US
dc.publisherChanRe Healthcareen_US
dc.relation.issuenumber1en_US
dc.relation.volume7en_US
dc.source.urihttps://dx.doi.org//10.15305/ijrci/v7i1/307en_US
dc.subjectchronic arthritisen_US
dc.subjectetanercepten_US
dc.subjectchikungunyaen_US
dc.titleManaging chikungunya arthritis using etanercepten_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijrci2019v7n1pc1.pdf
Size:
255.06 KB
Format:
Adobe Portable Document Format
Download
Collections
Internet Journal of Rheumatology and Clinical Immunology